drugset / Trial / NCT01887535
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-ascending dose JNJ-54861911 which is currently being developed for the treatment of Alzheimer's disease.
Timeline
- Start
- 2013-05
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atabecestat | Small molecule | 3 mg | Oral |
| Subject | Atabecestat | Small molecule | 10 mg | Oral |
| Subject | Atabecestat | Small molecule | 25 mg | Oral |
| Subject | Atabecestat | Small molecule | 30 mg | Oral |
| Subject | Atabecestat | Small molecule | 80 mg | Oral |
Indications
No indication recorded.